Affordable Access

deepdyve-link
Publisher Website

Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea.

Authors
  • Hoover, Rebecca M1
  • Erramouspe, John1
  • 1 1 Idaho State University, Pocatello, ID, USA.
Type
Published Article
Journal
Annals of Pharmacotherapy
Publisher
SAGE Publications
Publication Date
Mar 01, 2018
Volume
52
Issue
3
Pages
263–267
Identifiers
DOI: 10.1177/1060028017740139
PMID: 29094614
Source
Medline
Keywords
License
Unknown

Abstract

The topical α-agonist, oxymetazoline, is safe and effective for reducing persistent facial redness associated with erythematotelangiectatic subtype of rosacea. Health care practitioners selecting among treatments should consider not only the subtype of rosacea but also individual patient response, preference, and cost.

Report this publication

Statistics

Seen <100 times